Ignite Creation Date:
2024-05-05 @ 7:14 PM
Last Modification Date:
2024-10-26 @ 9:46 AM
Study NCT ID:
NCT00631475
Status:
COMPLETED
Last Update Posted:
2015-09-28
First Post:
2008-02-12
Brief Title:
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 BUILD 3 NCT00391443
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 NCT00391443
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BUILD OL
Brief Summary:
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 BUILD 3 NCT00391443 will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis IPF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None